Back to Journals » Psoriasis: Targets and Therapy » Volume 9

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential

Authors Chiricozzi A, De Simone C, Fossati B, Peris K

Received 14 February 2019

Accepted for publication 1 May 2019

Published 24 May 2019 Volume 2019:9 Pages 29—35

DOI https://doi.org/10.2147/PTT.S179283

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Uwe Wollina


Andrea Chiricozzi,1,2 Clara De Simone,1,2 Barbara Fossati,2 Ketty Peris1,2

1Institute of Dermatology, Catholic University, Rome, Italy; 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Abstract: Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.

Keywords: psoriasis, psoriatic arthritis, bimekizumab, bispecific agent, dual specific agent

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]